Claudio Laudani Compares Aspirin and P2Y12 Inhibitor Monotherapy in ACS Patients After PCI
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on LinkedIn:
“Aspirin: another nail in the coffin? (For ACS)
In this systematic review and meta-analysis, we compared the relative benefits of aspirin and P2Y12 inhibitor monotherapy after a short DAPT in ACS patients undergoing PCI.
At interaction analysis, the benefits of short DAPT compared to standard DAPT appear to be driven by P2Y12 inhibitor monotherapy, rather than aspirin monotherapy.
Indeed, P2Y12 inhibitor monotherapy reduced NACE, any bleeding and major bleeding, while aspirin monotherapy retrieved neutral results.
At indirect comparison through network meta-analysis, P2Y12 inhibitor monotherapy reduced NACE by 23% and any bleeding by 32% compared to aspirin monotherapy.
Finally, more robust and high quality evidence exist for P2Y12 inhibitor monotherapy, especially ticagrelor, and our trial sequential analysis reflected this result.”
Read the full article here.
Article: Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes
Authors: Claudio Laudani, Daniele Giacoppo, Giovanni Occhipinti, Mattia Galli, Antonio Greco, Marco Spagnolo, Luis Ortega-Paz, Francesco Costa, Dominick J. Angiolillo, Davide Capodanno
Stay updated on all scientific advances in the field with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis